Brea C. Lipe

Denosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study

Lytic bone lesions are a defining characteristic of multiple myeloma (MM) and one of its most significant clinical consequences. Bone-modifying agents, including the bisphosphonates zoledronic acid and pamidronate, as well as the receptor activator of nuclear factor-κB ligand (RA...